☆ 4.7 Article

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma

ONCOLOGIST (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?

Jacob J. Adashek et al.

Summary: The combination of targeted therapy and immunotherapy has significantly improved outcomes in the treatment of metastatic renal cell carcinoma. However, there is still a challenge in identifying biomarkers and predicting response to these agents. Targeting multiple clones within heterogenic tumors that respond to both types of therapy may explain the improved response rates observed in combination approaches.

DRUGS (2022)

Add to Collection

Article Oncology

Kidney Cancer, Version 3.2022

Robert J. Motzer et al.

Summary: The NCCN Guidelines for Kidney Cancer provide comprehensive treatment recommendations for renal cell carcinoma, covering screening, diagnosis, staging, surgery, and systemic therapy. Tumor histology and risk stratification of patients are important factors in treatment selection, considering efficacy, safety, evidence, and accessibility of agents.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective

In-Ho Kim et al.

Summary: Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide, resulting in approximately 170,000 deaths. Clear cell RCC is the most common subtype, accounting for about 85% of metastatic RCC cases. Immunotherapy with checkpoint inhibitors has shown promising results and become the standard of care for advanced clear cell RCC.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann-Alexandre Vano et al.

Summary: This study demonstrated the feasibility and positive impact of prospective patient selection based on tumor molecular phenotype to choose the most effective treatment between nivolumab with or without ipilimumab and a VEGFR-TKI in the first-line treatment of metastatic clear-cell renal cell carcinoma.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Chun Loo Gan et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States

Qianyi Zhang et al.

Summary: The study expanded the assessment of mortality variable and utilized a nationwide electronic health record database for data analysis. Compared with the National Death Index, the composite mortality variable showed high sensitivity, specificity, positive predictive value, negative predictive value, and +/- 15-day agreement across all 18 cancer types analyzed.

HEALTH SERVICES RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Evaluating eligibility criteria of oncology trials using real-world data and AI

Ruishan Liu et al.

Summary: The study found that using a data-driven approach to broaden trial eligibility criteria can increase the number of eligible patients and decrease the hazard ratio of overall survival. Many patients who were initially not eligible under the trial criteria could potentially benefit from the treatments.

NATURE (2021)

Add to Collection

Article Oncology

A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer

Daniel M. Geynisman et al.

Summary: In the 21st century, the diagnosis, evaluation, and management of patients with renal cell carcinoma have transformed from blunt surgical and largely ineffective medical treatments to nuanced and fine-tuned approaches based on biology, extent of disease, and patient preferences. This progress in kidney cancer over the past 25 years has been summarized in this review.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

Add to Collection

Article Oncology

Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics

Cameron M. Phillips et al.

CANCER (2020)

Add to Collection

Review Oncology

First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis

Fernando Sabino M. Monteiro et al.

CLINICAL GENITOURINARY CANCER (2020)

Add to Collection

Editorial Material Urology & Nephrology

Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer

Thomas Powles

EUROPEAN UROLOGY (2020)

Add to Collection

Editorial Material Oncology

Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap

Arnoud J. Templeton et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Reza Elaidi et al.

CANCERS (2020)

Add to Collection

Article Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, Research & Experimental

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer

Sandra D. Griffith et al.

ADVANCES IN THERAPY (2019)

Add to Collection

Article Medicine, General & Internal

Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis

Junpeng Wang et al.

EBIOMEDICINE (2019)

Add to Collection

Review Oncology

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Andrew W. Hahn et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Add to Collection

Review Urology & Nephrology

First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Christopher J. D. Wallis et al.

EUROPEAN UROLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

R. J. Motzer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Mathematical & Computational Biology

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

Peter C. Austin et al.

STATISTICS IN MEDICINE (2015)

Add to Collection

Review Gastroenterology & Hepatology

A Primer on Effectiveness and Efficacy Trials

Amit G. Singal et al.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2014)

Add to Collection

Article Oncology

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y. C. Heng et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Mathematical & Computational Biology

Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data

J Xie et al.

STATISTICS IN MEDICINE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.